You are here:

Archived: aztreonam (Cayston)

Advice

Following a full submission:
 
aztreonam lysine (Cayston®) is not recommended for use within NHS Scotland.
 
Indication under review: The suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 18 years and older.
 
Aztreonam lysine has demonstrated superiority in improving lung function and respiratory symptoms in one 28-day active-controlled study and two 28-day placebo-controlled studies in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. There are limited data to support the sustainability of the observed short term benefit over subsequent courses of treatment.
 
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC and, in addition, the company did not present a sufficiently robust economic case to gain acceptance by SMC.

Drug Details

Drug Name: aztreonam (Cayston)
SMC Drug ID: 753/12
Manufacturer: Gilead Sciences Ltd
Indication: For the suppressive therapy of chronic pulmonary infections due to Pseudomonas Aeruginosa in patients with cystic fibrosis (CF) aged 18 years and older.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 February 2012

Current Advice

Resubmission 12 January 2015

Back